Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620861
Title:
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Authors:
Mujica-Mota, R.; Varley-Campbell, J.; Tikhonova, I.; Cooper, C.; Griffin, E.; Haasova, M.; Peters, J.; Lucherini, S.; Talens-Bou, J.; Long, L.; Sherriff, D.; Napier, Mark; Ramage, J.; Hoyle, M.
Abstract:
Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine system.
Citation:
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. 2018, 22 (49):1-326 Health Technol Assess
Publisher:
NIHR
Journal:
Health technology assessment (Winchester, England)
Issue Date:
Sep-2018
URI:
http://hdl.handle.net/11287/620861
DOI:
10.3310/hta22490
PubMed ID:
30209002
Additional Links:
https://doi.org/10.3310/hta22490
Note:
This report is freely available online. Click on the link above to access the full-text
Type:
Journal Article; Systematic review
Language:
en
ISSN:
2046-4924
Appears in Collections:
Oncology; 2018 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMujica-Mota, R.en
dc.contributor.authorVarley-Campbell, J.en
dc.contributor.authorTikhonova, I.en
dc.contributor.authorCooper, C.en
dc.contributor.authorGriffin, E.en
dc.contributor.authorHaasova, M.en
dc.contributor.authorPeters, J.en
dc.contributor.authorLucherini, S.en
dc.contributor.authorTalens-Bou, J.en
dc.contributor.authorLong, L.en
dc.contributor.authorSherriff, D.en
dc.contributor.authorNapier, Marken
dc.contributor.authorRamage, J.en
dc.contributor.authorHoyle, M.en
dc.date.accessioned2018-10-04T13:34:46Z-
dc.date.available2018-10-04T13:34:46Z-
dc.date.issued2018-09-
dc.identifier.citationEverolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. 2018, 22 (49):1-326 Health Technol Assessen
dc.identifier.issn2046-4924-
dc.identifier.pmid30209002-
dc.identifier.doi10.3310/hta22490-
dc.identifier.urihttp://hdl.handle.net/11287/620861-
dc.description.abstractNeuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine system.en
dc.language.isoenen
dc.publisherNIHRen
dc.relation.urlhttps://doi.org/10.3310/hta22490en
dc.rightsArchived with thanks to Health technology assessment (Winchester, England)en
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en
dc.titleEverolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.en
dc.typeJournal Articleen
dc.typeSystematic reviewen
dc.identifier.journalHealth technology assessment (Winchester, England)en
dc.description.noteThis report is freely available online. Click on the link above to access the full-texten
dc.type.versionPublisheden

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.